{"id":18501,"date":"2022-12-14T16:46:02","date_gmt":"2022-12-14T16:46:02","guid":{"rendered":"https:\/\/clinlabint.com\/?p=18501"},"modified":"2022-12-14T16:46:02","modified_gmt":"2022-12-14T16:46:02","slug":"phoremost-and-thinkcyte-collaborate-to-advance-ai-based-drug-discovery","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/phoremost-and-thinkcyte-collaborate-to-advance-ai-based-drug-discovery\/","title":{"rendered":"PhoreMost and ThinkCyte collaborate to advance AI based drug discovery"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

PhoreMost and ThinkCyte collaborate to advance AI based drug discovery<\/h1>\/ in E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to \u2018Drugging the Undruggable\u00ae<\/sup>\u2019 disease targets, and ThinkCyte K.K, a biotechnology company pioneering novel cell analysis and sorting instruments, today announced a strategic research partnership aimed at advancing modern phenotypic drug screening using artificial intelligence (AI). The partnership leverages both companies\u2019 distinctive technologies in high-throughput drug discovery, PhoreMost\u2019s next-generation phenotypic screening platform, SITESEEKER\u00ae<\/sup>, and ThinkCyte\u2019s AI-driven cell characterization and sorting platform, Ghost Cytometry\u00ae<\/sup>, with the aim of developing differentiated therapies for a range of diseases with unmet clinical need.<\/h3>\n

<\/p>\n

Driven by advances in cell-based phenotypic screening tools and novel target discovery technologies, the power of Phenotypic Drug Discovery (PDD) lies in its unmatched ability to find completely new drug targets and disease mechanisms, providing not only new drug candidates, but a better understanding of disease. PhoreMost\u2019s SITESEEKER platform, based on the Company\u2019s core proprietary \u2018Protein Interference\u2019 (PROTEINi) technology, probes the entire proteome to systematically unmask new and unanticipated druggable sites, directly linking them to useful therapeutic functions. ThinkCyte has pioneered Ghost Cytometry, an approach that enables detection of novel, disease-related phenotypes. By combining SITESEEKER to identify novel druggable targets with Ghost Cytometry to identify subtle phenotypic changes in living cells, the partnership aims to develop an entirely unique approach to high-content phenotypic screening. The research partnership will drive ThinkCyte deeper into the field of early drug discovery and will contribute to PhoreMost\u2019s mission of \u2018Drugging the Undruggable\u00ae\u2019.<\/p>\n<\/div><\/section>
\n

\"\"<\/div><\/div><\/div>
\n

\u201cPhoreMost has embraced the revolution in computational methods to transform the way we approach modern drug discovery,\u201d <\/em>said<\/strong> Dr. Benedict Cross, CTO of PhoreMost. <\/strong>\u201cBy combining ThinkCyte\u2019s AI-based platform to detect novel, disease-related phenotypes with our SITESEEKER phenotypic screening platform, we hope to more efficiently uncover a broad range of novel targets and translate them into high-quality first-in-class therapeutic assets\u201d<\/em><\/p>\n

\u201cWe are very excited about the research partnership with PhoreMost, a leader in applying innovative approaches and technologies to open up new druggable spaces.\u201d <\/em>said<\/strong> Waichiro Katsuda, CEO at ThinkCyte. \u201c<\/strong>We have been privileged to work with drug discovery industry partners who share our vision of using AI to rethink traditional approaches in R&D and look forward to working together with PhoreMost to advance our technologies towards the shared goal of making meaningful impact for people suffering from serious diseases.\u201d<\/em><\/p>\n<\/div><\/section>
\n